[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myofascial-pain-syndrome-mps\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myofascial-pain-syndrome-mps":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100630937","imaging-metabolic-and-perfusion-changes-in-acupuncture-therapy-for-myofascial-pain-syndrome-100630937",false,"NCT07494162","Imaging Metabolic and Perfusion Changes in Acupuncture Therapy for Myofascial Pain Syndrome","IMPACT-MPS: Imaging Metabolic and Perfusion Changes in Acupuncture Therapy for Myofascial Pain Syndrome","IMPACT-MPS","Inclusion Criteria:\n\n* Ability to understand the purposes and risks of the trial and willingness to sign an informed consent form\n* Willingness and ability to comply with all protocol required procedures\n* Willingness to be randomized to receive either true acupuncture or sham acupuncture\n* Current self-report of chronic low back pain (cLBP) which has persisted for the past 3 months AND has resulted in pain on \\> 50% of days in the past 6 months\n* At least one palpable nodule or taut band in paraspinal, quadratus lumborum, or gluteal muscles\n* Reproduction of the patient's dominant pain with palpation of a muscle nodule or taut band\n* Predominantly paramedian pain (may be uni-lateral or bi-lateral)\n* Willing and able to lay motionless in a supine position at least twice, preferably thrice: 70-minute TB-PET\u002FCT scan\n* Willing and able to fast for at least 6 hours before and for the duration of the TB-PET\u002FCT scan\n* Willing to avoid strenuous exercise for 24 hours before the TB-PET\u002FCT scan visit\n* Willingness to practice effective contraception during the study.\n\nExclusion Criteria:\n\n* No Primary Care Physician\n* History of spine infection (discitis or osteomyelitis) or spine tumor\n* History of ankylosing spondylitis, rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, or lupus\n* Confounding conditions that are known to be responsible for inducing pain\n* Implants at or in the region of the sites of interest\n* Diagnosis of any vertebral fracture in the last 6 months\n* Cauda equina syndrome or lumbar radiculopathy with functional motor deficit (strength\\\u003C4\u002F5 on manual motor testing)\n* Spinal implants (including fixation hardware, spinal cord stimulator, intra-thecal pumps, that are present in the region of the sites of interest)\n* Predominantly central pain\n* Pain below the knee\n* Positive straight leg raise test\n* Symptomatic hip arthritis\n* Uncontrolled claustrophobia\n* Pregnant or lactating participants\n* Body weight more than 225 kg (496 pounds) due to the weight limitation of the scanner bed\n* Prisoners\n* Inability to speak, read, and write in the English language\n* Concurrent or prior enrollment in a separate research study involving a PET scan performed within the last 12 months for research purposes only.\n\nThat is, PET scans are not performed as part of a patient's treatment plan (e.g. standard of care, therapeutic purposes, or clinical care) and the research study did not intend to provide therapeutic benefit to the patient.\n\n•Any other criteria, which would make the participant unsuitable to participate in this study as determined by the Principal Investigator","ALL","18 Years",{"count":20,"type":21},64,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study will evaluate the clinical and biological effects of acupuncture for chronic low back pain associated with myofascial pain syndrome (MPS).\n\nIn this randomized, participant- and assessor-blinded clinical trial, 64 adults with chronic low back pain due to MPS will be assigned to receive either true acupuncture or sham acupuncture for eight weeks. Participants will undergo total-body positron emission tomography\u002Fcomputed tomography (TB-PET\u002FCT) imaging and complete standardized pain and functional questionnaires at baseline and after treatment.\n\nThe study will evaluate whether acupuncture improves pain and function compared with sham treatment and whether TB-PET\u002FCT imaging can detect changes in myofascial tissue metabolism and perfusion that correspond with clinical outcomes.",[27,28],"Myofascial Pain Syndrome (MPS)","Chronic Low-back Pain (cLBP)",[30,31,32,33,34,35],"acupuncture treatment","Total-Body PET","FDG PET","Myofascial Pain Syndrome","Chronic Low Back Pain","Imaging Biomarkers","RECRUITING","2026-06-15",{"date":39,"type":40},"2026-06-17","ACTUAL",{"date":42,"type":40},"2026-05-18",{"date":44,"type":21},"2030-04",{"name":46,"class":47},"University of California, Davis","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":48},"100620066","high-intensity-laser-therapy-for-trapezius-myofascial-pain-hilt-trap-study-100620066","NCT07352787","High-Intensity Laser Therapy for Trapezius Myofascial Pain (HILT-TRAP Study)","High-Intensity Laser Therapy for Trapezius Myofascial Pain Syndrome: Effects on Pain, ROM, Function, and Depression A Four-Phase Development, Validation, and Evaluation Study","HILT-TRAP Stud","Inclusion Criteria:\n\n* Adults aged 18 to 65 years\n* Clinically diagnosed trapezius myofascial pain syndrome\n* Duration of symptoms ≥ 4 weeks\n* Pain intensity ≥ 4 on NPRS\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Red-flag medical conditions (e.g., malignancy, spinal cord compression)\n* Neurological disorders affecting the neck or shoulder\n* Cognitive impairment or inability to communicate\n* Previous laser therapy to the neck\u002Fshoulder region within the last 6 months","65 Years",{"count":59,"type":21},104,[24],"This study aims to evaluate the effectiveness of optimized High-Intensity Laser Therapy (HILT) compared with sham treatment in patients with trapezius myofascial pain syndrome. Outcomes include pain intensity, cervical range of motion, functional disability, and depressive symptoms measured at baseline, post-intervention, and 16-week follow-up.",[27],[64,65,66,67,68],"High-Intensity Laser Therapy","Trapezius Myofascial Pain Syndrome","Randomized Controlled Trial","Neck Pain","Physiotherapy","NOT_YET_RECRUITING","2026-01-13",{"date":72,"type":40},"2026-01-20",{"date":74,"type":21},"2026-03-10",{"date":76,"type":21},"2027-04-10",{"name":78,"class":47},"Neveen Abd El Maksoad Kohaf",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":48},"100599321","phase-4-emg-based-evaluation-of-occlusal-splint-and-masseter-botox-effects-on-head-and-neck-muscles-100599321","NCT07082972","EMG-Based Evaluation of Occlusal Splint and Masseter Botox Effects on Head and Neck Muscles","Evaluation of the Effects of Occlusal Splint and Masseter Botulinum Toxin Injections on Head and Neck Muscles Using Electromyography","Inclusion Criteria:\n\n1. Having a diagnosis of myofascial pain syndrome\n2. No missing teeth\n3. No history of previous temporomandibular disorder treatment\n4. Absence of an arthrogenic temporomandibular disorder\n\nExclusion Criteria:\n\n* Pregnancy or lactation; osteoporosis and bisphosphonate use\n* Previous botulinum toxin injection to the masseter region\n* Bleeding disorders or use of anticoagulant medications\n* Presence of systemic muscular or neurological diseases (e.g., myasthenia gravis, ALS)\n* Active infection, open wound, or dermatological condition in the facial area\n* Undergoing other facial aesthetic procedures (e.g., fillers, PRP, etc.) within the last six months\n* Individuals with severe psychiatric disorders or those on regular psychiatric medications\n* Patients who are unlikely to comply with the study protocol or complete the follow-up period\n* Individuals with a body mass index (BMI) outside the normal range, including underweight or overweight participants, will be excluded from the study.","55 Years",{"count":88,"type":21},56,[90],"PHASE4","This randomized controlled clinical trial aims to evaluate the individual and combined effects of occlusal splint therapy and botulinum toxin type A (BTX-A) injections into the masseter muscle on the activity of head and neck muscles in patients diagnosed with myofascial pain syndrome (MPS). MPS is a common subtype of temporomandibular disorders (TMD), frequently involving the masticatory and cervical muscles. Despite various treatment modalities, there is still no universally accepted protocol. In this study, 56 adult participants of both sexes, without missing teeth and within a normal body mass index (BMI) range, will be randomly assigned to four groups: BTX-A injection only, occlusal splint only, combined BTX-A and splint therapy, and an untreated control group. Surface electromyography (EMG) will be used to assess muscle activity in the masseter, temporalis, sternocleidomastoid, splenius capitis, and trapezius muscles. EMG recordings will be performed at baseline, 4 weeks, and 12 weeks after the intervention. Pain levels and symptom severity will be assessed using the DC\u002FTMD symptom questionnaire and the Visual Analog Scale (VAS). BTX-A injections will be administered by a neurology specialist (20 IU per masseter muscle), and occlusal splints will be custom-fabricated and fitted for each participant. This study seeks to determine the neuromuscular effects of these treatments-both alone and in combination-on masticatory and cervical muscles and to provide insight into the development of more comprehensive and effective treatment strategies for MPS.",[27,93],"Masticatory Muscle Pain",[27,95,96,97,98,99,100,101,102],"Botulinum Toxin","Occlusal Splint","Bruxism","Head and neck muscles","Sternocleidomastoid muscle (SCM)","Masseter muscle","Splenius capitis muscle","Electromyography","2025-07-17",{"date":105,"type":40},"2025-07-24",{"date":107,"type":21},"2025-09-01",{"date":109,"type":21},"2026-12-01",{"name":111,"class":47},"Istanbul University"]